Canaccord Genuity Maintains Buy on Definium Therapeutics, Lowers Price Target to $58

Benzinga Newsdesk www.benzinga.com Negative 73.4%

Neg 73.4% Neu 0% Pos 0%

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and lowers the price target from $60 to $58.